# Short-course Radiation Followed by mFOLFOX-6 Plus COMPOUND 2055269 for Locally-advanced Rectal Adenocarcinoma

> **NCT03503630** · PHASE2 · UNKNOWN · sponsor: **Ali Shamseddine** · enrollment: 44 (actual)

## Conditions studied

- Locally Advanced Rectal Cancer

## Interventions

- **DRUG:** COMPOUND 2055269
- **RADIATION:** Radiation Therapy
- **DRUG:** mFOLFOX
- **PROCEDURE:** Total Mesorectal Excision

## Key facts

- **NCT ID:** NCT03503630
- **Lead sponsor:** Ali Shamseddine
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-07-20
- **Primary completion:** 2021-03-15
- **Final completion:** 2024-07-02
- **Target enrollment:** 44 (ACTUAL)
- **Last updated:** 2024-01-31

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03503630

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03503630, "Short-course Radiation Followed by mFOLFOX-6 Plus COMPOUND 2055269 for Locally-advanced Rectal Adenocarcinoma". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT03503630. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*